Pakistan journal of pharmaceutical sciences · 2026
Clinical evaluation of bevacizumab intravenous infusion-associated bleeding risk and vascular stress under a vascular‑protective management pathway in recurrent ovarian cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Tingting, Wan Lili, Wang Xin, Wu Dongyun, Li Aomei, Zang Jixian
Аннотация
BACKGROUND: Bevacizumab (BEV) is pivotal for anti-angiogenic therapy in recurrent ovarian cancer (ROC), but its real-world bleeding risk profile and standardized management remain to be refined, demanding tailored pharmacovigilance data for clinical decision-making.
OBJECTIVES: This single-center retrospective study characterized BEV-related bleeding events, explored the association between vascular protection management and coagulation-fibrinolysis/inflammation markers and provided bleeding risk prevention guidance.
METHODS: This single-center retrospective study was conducted in Nanjing, China, from October 2024 to September 2025, with follow-up completed by December 2025. Data were extracted from electronic medical records, laboratory information systems, pharmacy records, infusion records, and nursing documentation. Bleeding was graded per CTCAE v5.0; vascular protection metrics and dynamic changes of biochemical markers (Hb, PLT, FIB, D-dimer, and CRP) were collected and analyzed.
RESULTS: 22.5% had any-grade bleeding and 15.8% grade ≥2 bleeding, mostly mucocutaneous and clustered in early treatment. Compared to the non-bleeding group, the bleeding group exhibited higher concomitant drug use, a higher prevalence of hypertension, and lower vascular protection compliance (all P < 0.05). Additionally, this group experienced significant declines in Hb, PLT, and FIB, alongside elevated D-dimer and CRP levels (all P < 0.05).
CONCLUSION: BEV-related bleeding has distinct features, associated with concomitant drugs, inadequate vascular protection and abnormal coagulation/inflammation markers. Integrating pharmacovigilance and multispecialty vascular protection strategies can effectively mitigate bleeding risk and reduce treatment disruptions.
OBJECTIVES: This single-center retrospective study characterized BEV-related bleeding events, explored the association between vascular protection management and coagulation-fibrinolysis/inflammation markers and provided bleeding risk prevention guidance.
METHODS: This single-center retrospective study was conducted in Nanjing, China, from October 2024 to September 2025, with follow-up completed by December 2025. Data were extracted from electronic medical records, laboratory information systems, pharmacy records, infusion records, and nursing documentation. Bleeding was graded per CTCAE v5.0; vascular protection metrics and dynamic changes of biochemical markers (Hb, PLT, FIB, D-dimer, and CRP) were collected and analyzed.
RESULTS: 22.5% had any-grade bleeding and 15.8% grade ≥2 bleeding, mostly mucocutaneous and clustered in early treatment. Compared to the non-bleeding group, the bleeding group exhibited higher concomitant drug use, a higher prevalence of hypertension, and lower vascular protection compliance (all P < 0.05). Additionally, this group experienced significant declines in Hb, PLT, and FIB, alongside elevated D-dimer and CRP levels (all P < 0.05).
CONCLUSION: BEV-related bleeding has distinct features, associated with concomitant drugs, inadequate vascular protection and abnormal coagulation/inflammation markers. Integrating pharmacovigilance and multispecialty vascular protection strategies can effectively mitigate bleeding risk and reduce treatment disruptions.